Abstract
Migration of cancer cells is one of the key factors responsible for cancer metastasis. The elucidation of mechanisms responsible for the highly invasive potential of cancer cells can help to identify specific targets for the treatment of cancer patients. Highly invasive cancers are usually characterized by aberrant activity of specific intra- or extracellular molecules such as protein kinases, phosphatases, transcriptional factors, proteolytic enzymes, and others. Protein kinase C (PKC) and phosphatidylinositol 3-kinase (PI3K) are responsible for the constitutive activity of transcriptional factors NF-κB and AP-1 in some of the highly invasive cancers. Furthermore, NF-κB and AP-1 control the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), and expression of both uPA and uPAR correlates with invasive cancer cell phenotype and poor prognosis. The inhibition of PKC and PI3K signaling (through NF-κB and AP-1) suppressed the secretion of uPA, resulting in the inhibition of motility of highly invasive breast cancer cells. Therefore, inhibition of specific target molecules in common signaling pathway(s) responsible for metastatic spread can have potential clinical relevance. This review will summarize different approaches to targeting distinct signaling molecules involved in cancer invasion and metastasis.
Keywords: cancer invasion and metastasis, signaling pathways, upar
Current Cancer Drug Targets
Title: Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Volume: 4 Issue: 4
Author(s): Daniel Sliva
Affiliation:
Keywords: cancer invasion and metastasis, signaling pathways, upar
Abstract: Migration of cancer cells is one of the key factors responsible for cancer metastasis. The elucidation of mechanisms responsible for the highly invasive potential of cancer cells can help to identify specific targets for the treatment of cancer patients. Highly invasive cancers are usually characterized by aberrant activity of specific intra- or extracellular molecules such as protein kinases, phosphatases, transcriptional factors, proteolytic enzymes, and others. Protein kinase C (PKC) and phosphatidylinositol 3-kinase (PI3K) are responsible for the constitutive activity of transcriptional factors NF-κB and AP-1 in some of the highly invasive cancers. Furthermore, NF-κB and AP-1 control the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), and expression of both uPA and uPAR correlates with invasive cancer cell phenotype and poor prognosis. The inhibition of PKC and PI3K signaling (through NF-κB and AP-1) suppressed the secretion of uPA, resulting in the inhibition of motility of highly invasive breast cancer cells. Therefore, inhibition of specific target molecules in common signaling pathway(s) responsible for metastatic spread can have potential clinical relevance. This review will summarize different approaches to targeting distinct signaling molecules involved in cancer invasion and metastasis.
Export Options
About this article
Cite this article as:
Sliva Daniel, Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy, Current Cancer Drug Targets 2004; 4 (4) . https://dx.doi.org/10.2174/1568009043332961
DOI https://dx.doi.org/10.2174/1568009043332961 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors
CNS & Neurological Disorders - Drug Targets Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Neuro-Hormonal Regulation of Immune and Metabolic Function
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Taxus-based Drug Development
Current Drug Metabolism Nanoparticle as An Emerging Tool in Pulmonary Drug Delivery System
Micro and Nanosystems Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Current Pharmaceutical Biotechnology An Active and Low-cost Microwave Imaging System for Detection of Breast Cancer Using Back Scattered Signal
Current Medical Imaging Challenges from Clustering Analysis to Knowledge Discovery in Molecular Biomechanics
Current Bioinformatics Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Blockade of MUC1 Expression by Glycerol Guaiacolate Inhibits Proliferation of Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics of Human ABC Transporters: Detection of Clinically Important SNPs by SmartAmp2 Method
Current Pharmaceutical Biotechnology Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Proliferation of Breast Cancer Cells: Regulation, Mediators, Targets for Therapy
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Protein Kinase Inhibitors for the Treatment of Inflammatory Disease (Guest Editor: Mark R. Player)]
Current Topics in Medicinal Chemistry Vitamin D and miRNAs in Cancer
Current Gene Therapy Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets